Canada Life
KROS icon

Canada Life’s Keros Therapeutics KROS Stock Holding History

Canada Life’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,371
Closed -$116K – 2009
2024
Q4 		$116K Buy
7,371
+4,976
+208% +$259K ﹤0.01% 1790
2024
Q3 		$139K Sell
2,395
-5,425
-69% -$268K ﹤0.01% 1815
2024
Q2 		$358K Buy
7,820
+2,603
+50% +$140K ﹤0.01% 1748
2024
Q1 		$345K Buy
5,217
+2,822
+118% +$167K ﹤0.01% 1752
2023
Q4 		$95K Hold
2,395
– – ﹤0.01% 1954
2023
Q3 		$76K Buy
2,395
+1,497
+167% +$55.9K ﹤0.01% 2019
2023
Q2 		$36K Hold
898
– – ﹤0.01% 2043
2023
Q1 		$38K Hold
898
– – ﹤0.01% 2108
2022
Q4 		$43K Buy
898
+399
+80% +$18.6K ﹤0.01% 2101
2022
Q3 		$19K Hold
499
– – ﹤0.01% 2275
2022
Q2 		$14K Hold
499
– – ﹤0.01% 2328
2022
Q1 		$29K Hold
499
– – ﹤0.01% 2283
2021
Q4 		$29K Hold
499
– – ﹤0.01% 2299
2021
Q3 		$20K Hold
499
– – ﹤0.01% 2440
2021
Q2 		$21K Hold
499
– – ﹤0.01% 2476
2021
Q1 		$30K Hold
499
– – ﹤0.01% 2442
2020
Q4 		$35K Buy
+499
New +$31.4K ﹤0.01% 2396

Other funds holding KROS

Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Canada Life's KROS Position: Q1 2025 in Review

Canada Life sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 7,371 shares — an estimated $116K sold.

Canada Life first reported a position in KROS in Q4 2020 and held it in 17 quarters. The position peaked at $358K in Q2 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Canada Life reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Canada Life sold 7,371 Keros Therapeutics shares in Q1 2025, an estimated $116K.
  • Canada Life first reported a position in Keros Therapeutics in Q4 2020 and held it in 17 quarters.
  • Canada Life's Keros Therapeutics position peaked at $358K in Q2 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Canada Life's 13F filing for Q1 2025, filed 15 May 2025.